Last August, I wrote an article arguing that AbbVie (NYSE: ABBV ) appeared overbought and ripe for a short-term period of moving sideways, or even testing support. In particular, I proposed that ABBV was still a good company, but that share performanceZvi provides advisory services to companies, trusts, and individuals, including consulting expert services regarding retirement and estate planning. Zvi is admitted to practice law in the state of New York, where he offers cash management, Bitcoin, and Trust P ...

Business Operations - AbbVie operates as a single global business segment focused on innovative medicines and therapies, enabling resource allocation and performance assessment on a global basis[15]. - AbbVie maintains a global corporate administrative staff to support its comprehensive research, development, and commercialization efforts[15]. - AbbVie utilizes a combination of dedicated and regional commercial resources, focusing on securing prescriptions from healthcare providers[42]. - The company engages in various arrangements, including acquisitions and licensing, to enhance its product development and market presence[63]. Product Portfolio - AbbVie's immunology portfolio includes Humira, Skyrizi, and Rinvoq, addressing various autoimmune diseases across North America, the European Union, and Japan[16][18][20]. - Humira is approved for multiple conditions, including rheumatoid arthritis and Crohn's disease, and is sold in numerous markets worldwide, including Japan, China, and Brazil[16][18]. - Skyrizi is an IL-23 inhibitor approved for moderate to severe plaque psoriasis and ulcerative colitis, administered via subcutaneous injection or IV infusion[18][19]. - Rinvoq is a once-daily JAK inhibitor approved for several inflammatory diseases, including rheumatoid arthritis and atopic dermatitis, with a presence in multiple global markets[20][22]. - AbbVie's oncology products include Imbruvica and Venclexta, targeting complex blood cancers, with Imbruvica being one of the first therapies to receive multiple FDA designations[23][24]. - The aesthetics portfolio includes Botox Cosmetic and the Juvederm Collection, which hold market-leading positions in the U.S. and key global markets[27][28]. - AbbVie's neuroscience products, such as Vraylar and Ubrelvy, address difficult-to-treat neurologic diseases and are approved in various markets[30][33]. - Eye care products like Ozurdex and Lumigan are designed to address visual impairment and elevated intraocular pressure, available in the U.S. and numerous international markets[36][38]. - AbbVie's key products include treatments for hepatitis C, metabolic and hormone products, and endocrinology products for various conditions[39]. - Mavyret is approved for treating chronic HCV genotype 1-6 infection in patients aged 12 and older, with specific indications for those previously treated with certain HCV inhibitors[39]. - Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, marketed only in the United States[40]. - Linzess is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation, marketed as Linzess in the U.S. and Constella outside[41]. - AbbVie's medical device products, including breast implants, are primarily regulated as Class III medical devices, requiring extensive regulatory approval[97]. Research and Development - AbbVie invests significantly in research and development, focusing on compounds for complex, life-threatening diseases[66]. - The research and development process typically takes 8 to 12 years, with no guarantee of regulatory approval for new drugs[68]. - AbbVie collaborates with third parties, including biotechnology companies and academic institutions, to enhance its treatment portfolio[66]. - Regulatory approval in the U.S. requires substantial effort and financial resources, including successful completion of preclinical tests and clinical trials[70]. - Compliance with regulatory requirements is ensured through inspections by the FDA and other authorities, with potential consequences for non-compliance[71]. Market Environment - AbbVie faces significant competition from other pharmaceutical and biotechnology companies, particularly in immunology and oncology products[46]. - Humira faces direct biosimilar competition globally, impacting AbbVie's revenue from biologic products[48]. - AbbVie anticipates ongoing pricing pressures from insurers and providers, particularly in the U.S. and other countries[84]. - The Inflation Reduction Act of 2022 mandates government-set prices for select high-expenditure Medicare drugs starting in 2026, impacting revenue[88]. - In the European Union, pricing of pharmaceutical products is regulated, affecting market access and reimbursement[91]. - Japan's National Health Insurance system sets drug prices and mandates price cuts every two years, influencing product reimbursement[93]. Financial and Operational Insights - AbbVie's capital expenditures for pollution control in 2024 were approximately $13 million, with estimated operating expenditures of $35 million[103]. - The company employed approximately 55,000 employees in over 70 countries as of January 31, 2025[105]. - AbbVie has approximately $15.2 billion in foreign currency forward exchange contracts outstanding as of December 31, 2024, with a potential $1.5 billion decrease in fair value if there is a 10% appreciation in the underlying currencies[318]. - An increase in interest rates of 100 basis points would adversely impact the fair value of AbbVie's interest rate swap contracts by approximately $140 million[320]. - The company estimates that a 100 basis point increase in long-term interest rates would decrease the fair value of long-term debt by $4.6 billion[320]. - AbbVie has designated €3.1 billion in senior Euro notes as hedges of its net investments in certain foreign subsidiaries[319]. Corporate Responsibility and Employee Engagement - The company believes its operations comply with environmental protection laws, and it has ongoing remediation activities related to Superfund sites[104]. - AbbVie invests in employee development through competitive compensation and benefits, including health promotion programs and financial wellness support[107]. - The company emphasizes diversity and inclusion, conducting annual pay equity analyses to ensure equal opportunity for all employees[111].

Core Points - Richard A. Gonzalez will retire from AbbVie's board of directors effective July 1, 2025, and Robert A. Michael will assume the role of chairman [1] - Roxanne S. Austin expressed gratitude for Gonzalez's leadership and confidence in Michael's ability to guide AbbVie into its next growth phase [2] - Michael acknowledged Gonzalez's exceptional leadership and emphasized his commitment to AbbVie's success and impact on patients and shareholders [2] - Glenn F. Tilton will also retire from AbbVie's board effective July 1, 2025, after serving as lead independent director from 2013 to 2024 [2] About Robert A. Michael - Robert A. Michael has been appointed as chairman and is currently the CEO of AbbVie, with a history of leadership roles within the company [3] - He has over 32 years of experience in various sectors, including pharmaceuticals and diagnostics, and has played a key role in AbbVie's strategic development [3] - Michael's previous positions include president and chief operating officer, vice chairman, and chief financial officer, showcasing his extensive experience in corporate operations [3] About AbbVie - AbbVie aims to discover and deliver innovative medicines addressing serious health issues across key therapeutic areas such as immunology, oncology, and neuroscience [4] - The company is committed to making a significant impact on people's lives through its diverse product offerings, including those in the Allergan Aesthetics portfolio [4]

Core Viewpoint - Allergan Aesthetics is launching new AMI Training Centers to enhance training programs for aesthetic providers, aiming to improve patient outcomes and satisfaction [1][2][4]. Group 1: Training Centers Overview - The new AMI Training Centers will be strategically located in key markets and will offer a variety of courses for providers at all learning stages [1][2]. - The first center, AMI Orange County, is set to open in 2025, with additional centers planned for Atlanta and Austin [6]. Group 2: Educational Offerings - The training programs will include hands-on training, roundtable forums, national symposia, live webcasts, and a robust online learning platform [5][10]. - AMI Business Education will be launched on the AMI online platform in November 2024, providing free business operations courses to practitioners [6]. Group 3: Faculty and Curriculum - AMI faculty trainers will provide engaging, hands-on curricula to enhance clinical techniques and business acumen for participants [3][4]. - The training aims to empower aesthetic professionals with the necessary tools, skills, and confidence to succeed in their careers [3][4]. Group 4: Commitment to Excellence - Allergan Aesthetics is committed to setting a new standard for excellence in medical education through continuous investment in high-quality training programs [4][9]. - The AMI Training Centers exemplify this commitment by providing innovative training experiences that are unprecedented in the industry [4].

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like AbbVie (ABBV -1.23%), Amgen (AMGN -1.42%), and Gilead Sciences (GILD -2.04%).Resurging dividend royaltyKeith Speights (AbbVie): AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was p ...

Group 1: AbbVie - AbbVie has faced challenges, including the loss of patent exclusivity for its top-selling drug, Humira, leading to a significant drop in revenue and share price in early 2023 [2] - Despite setbacks, AbbVie's revenue for 2024 increased by 3.7% to $56.3 billion, and adjusted earnings per share decreased by 9% year over year to $10.12, partly due to acquisition-related expenses [4] - AbbVie is recognized as a Dividend King with 52 consecutive years of dividend increases and offers a forward yield of about 3.7%, making it attractive for income investors [5] Group 2: Gilead Sciences - Gilead Sciences' shares have increased by almost 29% over the trailing-12-month period, with a forward P/E of 12.9 indicating it may be undervalued [6] - The company's revenue for the first nine months of 2024 rose by 6% year over year to $21.2 billion, while adjusted EPS was $2.72, down almost 46% compared to the previous year due to acquisition-related charges [6][7] - Gilead has made significant progress in its pipeline, focusing on various therapeutic areas, including HIV and oncology, and has increased its dividend by about 79% over the past 10 years, with a forward yield of approximately 3.1% [8][9]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.Inflation is like a hidden force that stops for no one. One of the best ways to stay ahead of inflation is to buy income-generating assets that are tied to t ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1NORTH CHICAGO, ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.Perhaps the most promising AI application is its potential to revolutionize medicine by accelerating the drug discovery process to deliver more effective therapies. Several biotechnology companies are embracing these cutting-edge capabilities to unlock new growth oppo ...